|  |
| --- |
| **Case summary** |
| **Background (Age, Sex, Occupation, baseline function)** |
|  |
| **History of presentation/ reason for review** |
|  |
| **Current Medical History and Relevant Co Morbidities**  |
|  |
| **Current Medication and drug allergies (include OTC preparation and Herbal remedies)**  |
|  |
| **Lifestyle and Current Function (inc. Frailty score for >65yrs) alcohol/ smoking/ diet/ exercise**  |
|  |
| **“What matters to me” (Patient Ideas, Concerns and Expectations of treatment)** |
|  |
| **Results e.g biochemistry, other relevant investigations or monitoring** |
|  |
|  **Most recent relevant consultations** |
|  |

**Polypharmacy case study template (Please complete pages 1-3)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Domain** | **Steps** | **Process** | **Patient specific issues to address (please complete)** |
| **Aims** | **1.** | What matters to the patientproblems | **Review diagnoses and identify therapeutic objectives with respect to:*** Identify objectives of drug therapy
* Management of existing health problems. Prevention of future health concerns
 | **Agreed Plan** |
|  |
| **Need** | **2.** | Identify essential drug therapy | **Identify essential drugs (not to be stopped without specialist advice)*** Drugs that have essential replacement functions (e.g. thyroxine)
* Drugs to prevent rapid symptomatic decline (e.g. drugs for Parkinson’s disease, heart failure)
 | **Agreed Plan** |
| **3.** | Does the patient take unnecessary drug therapy? | **Identify and review the (continued) need for drugs*** What is medication for?
* with temporary indications
* with higher than usual maintenance doses
* with limited benefit/evidence of its use in general
* with limited benefit in the patient under review [(see Drug efficacy & applicability (NNT) table)](#NNTTable)
 | **Agreed Plan** |
| **Effectiveness** | **4.** | Are therapeutic objectives being achieved? | **Identify the need for adding/intensifying drug therapy in order to achieve therapeutic objectives** * to achieve symptom control
* to achieve biochemical/clinical targets
* to prevent disease progression/exacerbation
* is there a more appropriate medication that would help achieve goals
 | **Agreed Plan** |
| **Safety** | **5 .** | Does the patient have ADR/ Side effects or is at risk of ADRs/ side effects? Does the patient know what to do if they’re ill?  | **Identify patient safety risks by checking for*** if the targets set for the individual appropriate ?
* drug-disease interactions
* drug-drug interactions (see [ADR table](#ADRTable))
* monitoring mechanisms for high-risk drugs
* [risk of accidental overdosing](https://yellowcard.mhra.gov.uk/)

**Identify adverse drug effects by checking for*** specific symptoms/laboratory markers (e.g. hypokalaemia)
* cumulative adverse drug effects (see [ADR table](#ADRTable))
* drugs that may be used to treat side effects caused by other drugs

**Sick Day rule cards** |  |
| ***Agreed Plan*** |
| **Cost-effectiveness** | **6.** | Is drug therapy cost-effective? | **Identify unnecessarily costly drug therapy by*** Consider more cost-effective alternatives (but balance against effectiveness, safety, convenience)
 | **Agreed Plan** |
| **Patient centeredness** | **7.** | Is the patient willing and able to take drug therapy as intended? | **Does the patient understand the outcomes of the review?*** Consider Teach back

**Ensure drug therapy changes are tailored to patient preferences by*** Is the medication in a form the patient can take?
* Is the dosing schedule convenient?
* Consider what assistance the patient might have and when this is available
* Is the patient able to take medicines as intended

**Agree and communicate plan*** Discuss with the patient/carer/welfare proxy

therapeutic objectives and treatment priorities* Decide with the patient/ carer/ welfare proxies what medicines have an effect of sufficient magnitude to consider continuation or discontinuation
* Inform relevant healthcare and social care carers, changes in treatments across the care interfaces
 | **Agreed plan** |
|  |  |  |  |  |
| **Key Concepts in this case*** (Please summarize key points here)
 |